. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Mol Cancer Res. 2021 May 26;19(9):1510–1521. doi: 10.1158/1541-7786.MCR-21-0053

Table 1.

Baseline characteristics and clinical outcomes of the patients included in the study (n=24).

		N=24
Age (years) (median [IQR])		60.0 [56.0 – 66.3]
Gender (%)	Male	20 (83.3)
	Female	4 (16.7)
Race (%)	White	19 (79.2)
	Other	5 (20.8)
Line of therapy (%)	First	11 (45.8)
	Second	8 (33.3)
	Third or later	5 (20.8)
ECOG performance status (%)	ECOG 0	15 (62.5)
	ECOG 1	9 (37.5)
IMDC risk group (%)	Favorable Risk	13 (54.2)
	Intermediate Risk	11 (45.8)
Objective Response Rate (%)		79.2%
Best Objective Response by irRECIST (%)	Partial Response	19 (79.2)
	Stable Disease	4 (16.7)
	Progressive Disease	1 (4.2)